EP2563121A4 - Methods and compositions for protecting against neurotoxic agents - Google Patents

Methods and compositions for protecting against neurotoxic agents

Info

Publication number
EP2563121A4
EP2563121A4 EP11775615.5A EP11775615A EP2563121A4 EP 2563121 A4 EP2563121 A4 EP 2563121A4 EP 11775615 A EP11775615 A EP 11775615A EP 2563121 A4 EP2563121 A4 EP 2563121A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
protecting against
neurotoxic agents
against neurotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11775615.5A
Other languages
German (de)
French (fr)
Other versions
EP2563121A1 (en
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/771,476 external-priority patent/US20100310609A1/en
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of EP2563121A1 publication Critical patent/EP2563121A1/en
Publication of EP2563121A4 publication Critical patent/EP2563121A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
EP11775615.5A 2010-04-30 2011-04-29 Methods and compositions for protecting against neurotoxic agents Withdrawn EP2563121A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/771,476 US20100310609A1 (en) 2007-10-25 2010-04-30 Compositions and methods for treatment of neurodegenerative diseases
US41389910P 2010-11-15 2010-11-15
US201161454409P 2011-03-18 2011-03-18
PCT/US2011/034508 WO2011137317A1 (en) 2010-04-30 2011-04-29 Methods and compositions for protecting against neurotoxic agents

Publications (2)

Publication Number Publication Date
EP2563121A1 EP2563121A1 (en) 2013-03-06
EP2563121A4 true EP2563121A4 (en) 2016-05-11

Family

ID=44861925

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11775615.5A Withdrawn EP2563121A4 (en) 2010-04-30 2011-04-29 Methods and compositions for protecting against neurotoxic agents

Country Status (11)

Country Link
EP (1) EP2563121A4 (en)
JP (1) JP5941908B2 (en)
KR (1) KR20130113314A (en)
CN (1) CN103002734A (en)
AU (1) AU2011245223B2 (en)
BR (1) BR112012027905A2 (en)
CA (1) CA2798127A1 (en)
EA (1) EA201201483A1 (en)
IL (1) IL222757A0 (en)
MX (1) MX2012012634A (en)
WO (1) WO2011137317A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
AU2011289172B2 (en) * 2010-08-12 2015-09-24 Revalesio Corporation Compositions and methods for treatment of taupathy
JP6159584B2 (en) * 2012-06-14 2017-07-05 松本　高明 Infusion, infusion production method and infusion device
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
US20180243247A1 (en) * 2017-02-28 2018-08-30 Bryan J. Katz Drug combinations for cerebrovascular disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004224397A1 (en) * 2003-03-20 2004-10-07 Aquaphotonics, Inc. Micro-cluster compositions
ITMI20061737A1 (en) * 2006-09-12 2008-03-13 Snam Progetti PROCEDURE FOR THE TRANSPORT OF SULFUR TO LOW RISK AND TO ZERO EMISSION FROM SOLID SULFUR DEPOSITS IN BLOCKS OF CONSIDERABLE DIMENSIONS
US20100310609A1 (en) * 2007-10-25 2010-12-09 Revalesio Corporation Compositions and methods for treatment of neurodegenerative diseases
US9745567B2 (en) * 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
CA2722658C (en) * 2008-04-28 2018-09-18 Richard L. Watson Compositions and methods for treating multiple sclerosis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ASHUTOSH AGARWAL ET AL: "Principle and applications of microbubble and nanobubble technology for water treatment", CHEMOSPHERE., vol. 84, no. 9, 1 August 2011 (2011-08-01), GB, pages 1175 - 1180, XP055234995, ISSN: 0045-6535, DOI: 10.1016/j.chemosphere.2011.05.054 *
CHAPLIN MARTIN: "Nanobubbles (ultrafine bubbles)", 6 November 2015 (2015-11-06), pages 1 - 12, XP055235029, Retrieved from the Internet <URL:http://www1.lsbu.ac.uk/water/nanobubble.html> [retrieved on 20151209] *
LEE ET AL: "Phosphatidylinositol-3-kinase activation blocks amyloid beta-induced neurotoxicity", TOXICOLOGY, LIMERICK, IR, vol. 243, no. 1-2, 14 December 2007 (2007-12-14), pages 43 - 50, XP022391166, ISSN: 0300-483X *
See also references of WO2011137317A1 *
USHIKUBO F Y ET AL: "Evidence of the existence and the stability of nano-bubbles in water", COLLOIDS AND SURFACES. A, PHYSICACHEMICAL AND ENGINEERING ASPECTS, ELSEVIER, AMSTERDAM, NL, vol. 361, no. 1-3, 20 May 2010 (2010-05-20), pages 31 - 37, XP027030201, ISSN: 0927-7757, [retrieved on 20100311] *

Also Published As

Publication number Publication date
CN103002734A (en) 2013-03-27
AU2011245223A1 (en) 2013-01-10
IL222757A0 (en) 2012-12-31
AU2011245223B2 (en) 2015-11-19
BR112012027905A2 (en) 2015-09-08
EA201201483A1 (en) 2013-04-30
JP5941908B2 (en) 2016-06-29
KR20130113314A (en) 2013-10-15
CA2798127A1 (en) 2011-11-03
WO2011137317A1 (en) 2011-11-03
EP2563121A1 (en) 2013-03-06
JP2013529195A (en) 2013-07-18
MX2012012634A (en) 2013-02-26

Similar Documents

Publication Publication Date Title
IL263729A (en) Compositions and methods for the removal of biofilms
HK1246715A1 (en) Compositions and methods for targeted thermomodulation
ZA201209259B (en) Uses and compositions
GB201014618D0 (en) Respirtory protection equipment
EP2552953A4 (en) Frizzled-binding agents and uses thereof
ZA201208948B (en) Modified beta-lactamases and methods and uses related thereto
EP2629742A4 (en) Hair-mending compositions and associated methods
EP2575825A4 (en) Compositions and methods for treating depression
GB201113485D0 (en) Corrosion protection
PL2501847T3 (en) Protective glove
EP2533645A4 (en) Methods and compositions for improving cognitive function
EP2601269A4 (en) Anti-settling compositions and methods for use
EP2609160A4 (en) Protective coating composition
EP2563121A4 (en) Methods and compositions for protecting against neurotoxic agents
EP2632460A4 (en) Compositions and methods for treating tuberculosis
EP2931280A4 (en) Methods and compositions for inhibiting cnksr1
HK1167522A1 (en) Protection device
HK1201451A1 (en) Compositions and methods
GB201018650D0 (en) Methods and compositions
HK1254904B (en) Compositions and methods for the alteration of xlhed phenotypes
HK1170854A1 (en) Combination of appliances for protecting against surges
HK1167521A1 (en) Protection device
EP2686335A4 (en) Decorin compositions and use thereof
HK1167350A1 (en) Methods and compositions for protecting and treating neuroinjury
EP2603610A4 (en) Methods and compositions for diagnosing and treating lupus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20170317